Compare ALKT & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKT | SDGR |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2021 | 2020 |
| Metric | ALKT | SDGR |
|---|---|---|
| Price | $12.73 | $29.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $18.00 | ★ $25.86 |
| AVG Volume (30 Days) | 2.1M | ★ 2.3M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | $152,159,000.00 | ★ $255,869,000.00 |
| Revenue This Year | $19.44 | N/A |
| Revenue Next Year | $16.64 | $3.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.68 | 23.29 |
| 52 Week Low | $12.10 | $10.95 |
| 52 Week High | $24.47 | $33.78 |
| Indicator | ALKT | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 32.86 | 62.02 |
| Support Level | N/A | $27.69 |
| Resistance Level | $17.81 | $31.59 |
| Average True Range (ATR) | 0.65 | 1.93 |
| MACD | 0.13 | 0.40 |
| Stochastic Oscillator | 15.77 | 87.77 |
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.